Lori Anne Kunkel is on the board of Nurix Therapeutics, Inc., Oric Pharmaceuticals, Inc. and K36 Therapeutics, Inc. and Owner at Lak505, LLC.

In her past career she was Vice President-Clinical Development at Xencor, Inc., Chief Medical Officer of Syndax Pharmaceuticals, Inc., Chief Medical Officer at ACT Biotech, Inc., Principal at XOMA Corp., Vice President-Medical Affairs for Genitope Corp., Chief Medical Officer for Pharmacyclics LLC, Director at Tocagen, Inc., Chief Medical Officer for Proteolix, Inc., Director at Loxo Oncology, Inc., Associate Director-Clinical Development at Chiron Corp., Head-Clinical Scientist at Genentech, Inc., Principal at Onyx Pharmaceuticals, Inc., Principal at ZymoGenetics, Inc., Principal at Salmedix, Inc., Principal at DNAX Research Institute of Molecular & Cellular Biology, Inc and Member-Bone Marrow Transplant Unit at the University of California.

She received an undergraduate degree from the University of California San Diego and a doctorate from the University of Southern California.